International Medical Research Frontier

Objective To investigate the clinical efficacy of bevacizumab combined with paclitaxel and carboplatin as a chemotherapy regimen in patients with advanced ovarian cancer. Methods The 96 advanced ovarian cancer patients admitted to our hospital from 2020 to 2021 were divided into research group and control group, with 48 patients in each group. The control group of patients used paclitaxel plus carboplatin combined chemotherapy regimen, and the study group of patients used bevacizumab plus paclitaxel and carboplatin combined chemotherapy regimen for 6 months. The clinical effects of patients, serology and side reactions before and after treatment were compared in both groups. Results The total response rate of the patients in the study group was 68.75% higher than the 43.75% in the control group, (2=6.095, P=0.0014). Blood drug index was significantly lower in both groups, and the study group was lower than the control group (P <0.05). The incidence of side effects of grade III and above in the study group was 18.75% (9 / 48), and 14.58% (7 / 48) in the control group, with no significant difference (P> 0.05). Conclusion Bevacizumab combined with paclitaxel and carboplatin chemotherapy has an obvious therapeutic effect on advanced ovarian tumors, which can significantly improve the serological index and quality of life of patients, and the side effects are not obvious, and the quality of life of patients has been improved, which can be popularized.

Bevacizumab; paclitaxel; carboplatin; advanced ovarian cancer; clinical effects; adverse effects